ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sotatercept

Also written as “Sotatercept”, “Sotatercept 0.3 mg/kg” and “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”.

Its studies are mostly in Pulmonary Arterial Hypertension · Anemia · Hypertension, Pulmonary · Multiple Myeloma · beta-Thalassemia, led by 2 companies.

Drug pageSotatercept: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 15, 202626 company-led studies, 8 open or runningNext primary completion: Mar 21, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only228 open or runningphase 4since May 15, 2026May 22, 2009Mar 21, 2028phase 4 · NCT07899905
Bristol-Myers Squibb40 open or runningphase 2since Sep 3, 2008Sep 3, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2008First study: phase 2 study in Multiple MyelomaFirst studyNCT00747123 · 30 enrolled · Russian Federation
  2. Jun 16, 2010Phase 2 study in AnemiaNCT01146574 · 50 enrolled · United States
  3. Apr 3, 2012Phase 2 study in beta-ThalassemiaNCT01571635 · 46 enrolled · France, Greece, Italy and more
  4. Nov 26, 2013Phase 2 study in AnemiaNCT01999582 · 50 enrolled · Belgium, Germany, Portugal and more

TargetBeta

INHBA →read by rule
“Inhibin beta A chain inhibitor”ChEMBL 37, by rule

Other programs on INHBA

ProgramCompanyFurthest phaseStudies
garetosmabruleRegeneron Pharmaceuticalsphase 39

Studies

All 4 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01999582Anemia · Belgium, Germany, Portugal and more2CompletedAug 31, 201650
NCT01571635beta-Thalassemia · France, Greece, Italy and more2TerminatedJul 2, 201546
NCT01146574Anemia · United States2CompletedMar 7, 201650
NCT00747123Multiple Myeloma · Russian Federation2CompletedAug 1, 200930

How it is read

Names in the registry

  • “Sotatercept”, 22 entries
  • “Sotatercept 0.3 mg/kg”, 1 entry
  • “Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg”, 1 entry
  • “Sotatercept Autoinjector”, 1 entry
  • “ACE-011”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.